Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial.
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial.
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform